CD22 and non-Hodgkin lymphoma: However, an in vitro study evaluating an anti-CD22-DM1 ADC against 18 different non-Hodgkin lymphoma (NHL) cell lines showed that sensitivity to the cytotoxic payload (i.e., DM1) was more predictive of response than antigen expression levels [15].